...Wingless-type MMTV integration site family member BioCentury Staff Viaskin Peanut (DBV-712) PNT2002 KarXT, LY246708 plus trospium chloride, xanomeline plus trospium chloride RXC006 Qinlock...

...billion in market cap Monday after reporting data from its Phase II study of KarXT xanomeline/trospium chloride...

...xanomeline, which is an agonist of muscarinic acetylcholine receptor M1 (CHRM1; HM1) and M4, with trospium chloride...
...CHRM4 (HM4) - Muscarinic acetylcholine receptor M4 Paul Bonanos, Associate Editor KarXT, LY246708 plus trospium chloride, xanomeline plus trospium chloride Karuna...

...Data are due this year from a Phase II trial of Karuna's lead candidate KarXT xanomeline/trospium chloride...

...By late 2019, Karuna expects data from a Phase II trial of lead program KarXT xanomeline/trospium chloride...

...to date. By late 2019, Karuna expects data from a Phase II trial of KarXT xanomeline/trospium chloride...
...receptors M1 and M4 that has shown efficacy in CNS disorders, by combining it with trospium chloride...

...Karuna intends to execute on its broader ambitions for lead program KarXT xanomeline/trospium chloride beyond schizophrenia, including...
...of CHRM1 and CHRM4 that has shown efficacy in CNS disorders, by combining it with trospium chloride...
...CHRM4 (HM4) - Muscarinic acetylcholine receptor M4 Paul Bonanos, Assistant Editor KarXT, LY246708 plus trospium chloride, xanomeline plus trospium chloride Karuna...

...and Karuna Chairman Steven Paul, as well as undisclosed other backers. Karuna believes its KarXT xanomeline/trospium chloride...
...xanomeline, which is an agonist of muscarinic acetylcholine receptor M1 (CHRM1; HM1) and M4, with trospium chloride...
...company would consider licensing other assets opportunistically. Paul Bonanos, Assistant Editor KarXT, LY246708 plus trospium chloride, xanomeline plus trospium chloride Karuna...

...Steven Paul, PureTech Health plc (LSE:PRTC) and other undisclosed investors. Karuna's lead product is KarXT xanomeline/trospium chloride...
...candidate combines xanomeline, an agonist of muscarinic acetylcholine receptor M1 (CHRM1; HM1) and CHRM4, with trospium chloride...
...Lilly and Co. (NYSE:LLY). Karuna Pharmaceuticals Inc., Boston, Mass. Sandi Wong KarXT, LY246708 plus trospium chloride, xanomeline plus trospium chloride Eli...

...Steven Paul, PureTech Health plc (LSE:PRTC) and other undisclosed investors. Karuna's lead product is KarXT xanomeline/trospium chloride...
...candidate combines xanomeline, an agonist of muscarinic acetylcholine receptor M1 (CHRM1; HM1) and CHRM4, with trospium chloride...
...license to xanomeline from Eli Lilly and Co. (NYSE:LLY). Sandi Wong KarXT, LY246708 plus trospium chloride, xanomeline plus trospium chloride Karuna...